Plain language summary of the ARAMIS study: Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer

The ARAMIS trial looked at the role of the drug darolutamide in treating patients with nonmetastatic, castration-resistant prostate cancer. The results of the study were recently published in the New England Journal of Medicine. A plain language summary of the study has subsequently been published in Future Oncology, which helps patients, their caregivers, patient advocates and healthcare professionals understand the results of the trial. This Animated Video provides an overview of the plain language summary.

Read the plain language summary at https://www.futuremedicine.com/doi/10.2217/fon-2020-1291

Original publications:

Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial
K Fizazi, Ian Blue & Joel T Nowak
Future Oncology 17(14), 1699-1707 (2021) https://www.futuremedicine.com/doi/10.2217/fon-2020-1291

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi, Neal Shore, Teuvo L Tammela et al.
New England Journal of Medicine 383, 1040-1049 (2020) https://www.nejm.org/doi/full/10.1056/NEJMoa2001342

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi, Neal Shore, Teuvo L Tammela et al.
New England Journal of Medicine 380, 1235-1246 (2019) https://www.nejm.org/doi/full/10.1056/NEJMoa1815671